| Literature DB >> 28434822 |
Gerda B Toth1, Csanad G Varallyay2, Andrea Horvath1, Mustafa R Bashir3, Peter L Choyke4, Heike E Daldrup-Link5, Edit Dosa6, John Paul Finn7, Seymur Gahramanov8, Mukesh Harisinghani9, Iain Macdougall10, Alexander Neuwelt11, Shreyas S Vasanawala12, Prakash Ambady1, Ramon Barajas2, Justin S Cetas13, Jeremy Ciporen13, Thomas J DeLoughery14, Nancy D Doolittle1, Rongwei Fu15, John Grinstead16, Alexander R Guimaraes2, Bronwyn E Hamilton2, Xin Li17, Heather L McConnell1, Leslie L Muldoon1, Gary Nesbit2, Joao P Netto18, David Petterson2, William D Rooney17, Daniel Schwartz19, Laszlo Szidonya1, Edward A Neuwelt20.
Abstract
Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material. Published by Elsevier Inc.Entities:
Keywords: chronic kidney disease; magnetic resonance imaging; nephrotoxicity
Mesh:
Substances:
Year: 2017 PMID: 28434822 PMCID: PMC5505659 DOI: 10.1016/j.kint.2016.12.037
Source DB: PubMed Journal: Kidney Int ISSN: 0085-2538 Impact factor: 10.612